India===Indian Council of Medical Research

The India===Indian Council of Medical Research (ICMR) conducted and published a study through its India===National Institute for Research in Tuberculosis (ICMR-NIRT) demonstrating the cost-effectiveness and improved health outcomes of shorter, all-oral treatment regimens for multidrug-resistant tuberculosis in India. This research provides crucial evidence to support the adoption of these new regimens.

The India===Indian Council of Medical Research (ICMR) maintains the National Cancer Registry, to which data validated by the Mehdi Nawaz Jung Institute of Oncology and Regional Cancer Centre will be submitted.

The India===Indian Council of Medical Research is overseeing the Phase III trials of DengiAll in India. Its involvement ensures regulatory compliance and scientific rigor for the vaccine's development.

The India===Indian Council of Medical Research (ICMR) is represented by its Director General, Rajiv Bahl, who is also the Secretary of DHR, indicating its involvement in the healthcare research and policy aspects of the event.

The India===Indian Council of Medical Research (ICMR) conducted a survey (INDIAB) in 2023, estimating the significant diabetes burden in India, which provides context for the importance of accurate diagnostic tools discussed in The Lancet study.